Add-on Acquisition • Life Science

Recipharm Acquires Arranta Bio

On February 18, 2022, Recipharm acquired life science company Arranta Bio from Ampersand Capital Partners

Acquisition Context
  • This is Recipharm’s 12th transaction in the Life Science sector.
  • This is Recipharm’s 3rd transaction in the United States.
  • This is Recipharm’s 2nd transaction in Massachusetts.

Explore All 3116 Add-on Acquisition Life Science Deals - Search the Database Free


M&A Deal Summary

Date February 18, 2022
Target Arranta Bio
Sector Life Science
Buyer(s) Recipharm
Sellers(s) Ampersand Capital Partners
Deal Type Add-on Acquisition
Advisor(s) Morgan Stanley (Financial)
Goodwin Procter (Legal)

Target Company

Arranta Bio

Watertown, Massachusetts, United States
Arranta Bio is a contract development and manufacturing organization (CDMO) specifically established to focus on serving companies seeking to develop and commercialize therapies targeting the human microbiome. Arranta Bio was founded in 2019 and is based in Watertown, Massachusetts.
Explore More Deals

Browse All 215,262 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

Recipharm

Stockholm, Sweden

Category Company
Founded 1995
Sector Life Science
Employees7,383
DESCRIPTION

Recipharm is a global Pharma CDMO providing a full-service offering to leading Pharmaceutical companies and Biotechs globally. Recipharm was founded in 1995 and is based in Stockholm, Sweden.


Deal Context for Buyer #
Overall 18 of 18
Sector: Life Science 12 of 12
Type: Add-on Acquisition 9 of 9
State: Massachusetts 2 of 2
Country: United States 3 of 3
Year: 2022 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-02-18 Vibalogics

Boxborough, Massachusetts, United States

Vibalogics has operated as a specialized global Contract Development and Manufacturing Organization (CDMO) offering process and analytical development, manufacturing, testing, and fill-finish services to innovators developing transformational virotherapy products. Vibalogics GmbH was founded in 2002 and is based in Boxborough, Massachusetts.

Buy -

Seller Profile 1

SELLER

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor Investor


Category Growth Capital Firm
Founded 1988
PE ASSETS 3.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.


Deal Context for Seller #
Overall 50 of 56
Sector: Life Science 22 of 26
Type: Add-on Acquisition 36 of 39
State: Massachusetts 13 of 14
Country: United States 48 of 51
Year: 2022 3 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-02-18 Vibalogics

Boxborough, Massachusetts, United States

Vibalogics has operated as a specialized global Contract Development and Manufacturing Organization (CDMO) offering process and analytical development, manufacturing, testing, and fill-finish services to innovators developing transformational virotherapy products. Vibalogics GmbH was founded in 2002 and is based in Boxborough, Massachusetts.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-03-01 BioEcho Life Sciences

Koln, Germany

BioEcho Life Sciences specializes in nucleic acid sample preparation tools for clinical, biotech, life sciences research, agricultural, and industrial applications. BioEcho Life Sciences was formed in 2016 and is based in Koln, Germany.

Buy -